Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.